Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to ...

IBI363 simultaneously and selectively inhibits the PD-1/PD-L1 pathway and activates the IL-2 pathway. IBI363 has recently received multiple FTD and BTD designations, signifying regulatory recognition ...